Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

241.67 +2.48 (+1.04%)
Streaming Delayed Price Updated: 3:28 PM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 651,161
Open 240.24
Bid (Size) 241.50 (100)
Ask (Size) 241.84 (300)
Prev. Close 239.19
Today's Range 234.51 - 243.03
52wk Range 125.38 - 256.36
Shares Outstanding 137,533,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an... 
Via MarketMinute
News headline image
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that... 
Via MarketMinute

Performance

YTD
+5.6%
+5.6%
1 Month
+5.8%
+5.8%
3 Month
+34.7%
+34.7%
6 Month
+62.9%
+62.9%
1 Year
+45.8%
+45.8%

More News

Read More
News headline image
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
From Natera, Inc.
Via Business Wire
News headline image
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
From Natera, Inc.
Via Business Wire
News headline image
2 Cash-Heavy Stocks to Keep an Eye On and 1 We Question
Via StockStory
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
From Natera, Inc.
Via Business Wire
News headline image
The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
3 Growth Stocks with Explosive Upside
Via StockStory
Topics Energy
News headline image
3 Reasons We’re Fans of Natera (NTRA)
Via StockStory
Topics Stocks
News headline image
3 Market-Beating Stocks Worth Your Attention
Via StockStory
News headline image
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
From Natera, Inc.
Via Business Wire
News headline image
Natera Acquires Foresight Diagnostics
From Natera, Inc.
Via Business Wire
News headline image
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
From Natera, Inc.
Via Business Wire
News headline image
3 Cash-Producing Stocks with Solid Fundamentals
Via StockStory
News headline image
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks ↗
Via The Motley Fool
Topics Artificial Intelligence

Frequently Asked Questions

Is Natera, Inc. - Common Stock publicly traded?
Yes, Natera, Inc. - Common Stock is publicly traded.
What exchange does Natera, Inc. - Common Stock trade on?
Natera, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Natera, Inc. - Common Stock?
The ticker symbol for Natera, Inc. - Common Stock is NTRA on the Nasdaq Stock Market
What is the current price of Natera, Inc. - Common Stock?
The current price of Natera, Inc. - Common Stock is 241.67
When was Natera, Inc. - Common Stock last traded?
The last trade of Natera, Inc. - Common Stock was at 01/15/26 03:28 PM ET
What is the market capitalization of Natera, Inc. - Common Stock?
The market capitalization of Natera, Inc. - Common Stock is 33.24B
How many shares of Natera, Inc. - Common Stock are outstanding?
Natera, Inc. - Common Stock has 33B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.